EGFR and KRAS: Approximately 30% to 50% of colorectal tumours are known to have a mutated (abnormal) KRAS, indicating that up to 50% of patients with CRC might respond to anti-EGFR antibody therapy, they only have a reasonable opportunity to derive clinical benefit from the therapy. This evidence concerns the gene KRAS and colorectal neoplasm.